Sign in

    Dara Azar

    Research Analyst at Stifel

    Dara Azar is an equity research analyst at Stifel, specializing in covering the energy and oil & gas sectors with a focus on upstream exploration & production companies. While detailed public performance metrics and individual company coverage information for Azar are not readily available, their role at Stifel includes delivering fundamental research and investment recommendations to institutional clients. Career history, credentials, prior positions, and regulatory licenses are not disclosed through publicly accessible sources, and there is no evidence of notable national rankings or industry honors on major analytic platforms. Azar's profile reflects expertise within the energy domain, supporting Stifel's coverage in capital markets and investment research.

    Dara Azar's questions to Kura Oncology (KURA) leadership

    Dara Azar's questions to Kura Oncology (KURA) leadership • Q4 2024

    Question

    Dara Azar, on for Brad Canino at Stifel, questioned whether the EMA might have a different view than the FDA on MRD negativity as an endpoint and how the KOMET-017 trial would support global approval. She also asked if the data cut would be consistent between the ASCO presentation and the NDA submission.

    Answer

    CMO Dr. Mollie Leoni clarified that the U.S. accelerated approval would target the MRD endpoint, while survival-based endpoints would support EU approval. She also confirmed that the patient population and data denominator will be the same for the medical meeting presentation and the NDA submission, ensuring consistency.

    Ask Fintool Equity Research AI

    Dara Azar's questions to AFMD leadership

    Dara Azar's questions to AFMD leadership • Q3 2024

    Question

    Speaking on behalf of Brad Canino, he asked how the upcoming ORR data for AFM24 could inform expectations for future PFS data and what level of data maturity or clarity on the approval path is required by potential partners for a deal.

    Answer

    The company explained that a strong ORR would confirm the mechanism's ability to overcome PD-1 resistance, but the mature PFS data, expected in H1 2025, will be the key driver for final decisions. For partnerships, they are open to discussions across the pipeline and believe they are approaching the level of data maturity and patient numbers that potential partners are looking for to engage in more serious discussions.

    Ask Fintool Equity Research AI

    Dara Azar's questions to Summit Therapeutics (SMMT) leadership

    Dara Azar's questions to Summit Therapeutics (SMMT) leadership • Q2 2024

    Question

    Dara Azar inquired about the data disclosure timeline for the HARMONi-2 trial at the World Lung conference, the maturity of the Overall Survival (OS) data, what would be considered a strong Progression-Free Survival (PFS) result, and plans for future Phase III trials.

    Answer

    Executive Dave Gancarz explained the World Lung conference's abstract release process, noting that full details for a late-breaker like HARMONi-2 might be held until the conference. He and Chief Medical Officer Dr. Allen Yang confirmed that OS data is still very immature. Dr. Yang added that the study hitting its interim analysis early speaks to the strength of the PFS data, but declined to comment on specific results. He also suggested that announcements on additional Phase III plans could come at World Lung.

    Ask Fintool Equity Research AI